## Priority question for written answer P-005537/2021 to the Commission Rule 138

Rule 138
Samira Rafaela (Renew)

Subject: Openness and transparency in COVID-19 vaccine contracts

The Commission procured COVID-19 vaccines on behalf of EU Member States, and was successful in signing various contracts with pharmaceutical companies producing vaccines. Since January 2021, Parliament has requested openness and transparency on the contracts signed by the Commission with pharmaceutical companies. Yet to date, the Commission has only made redacted contracts available for public scrutiny. Openness and transparency on COVID-19 vaccine contracts is needed. The public should be able to scrutinise entire contracts and assess all their different aspects.

- 1. Why has the Commission so far refused to publish the unredacted contracts?
- 2. Does the Commission agree that the public should be able to scrutinise all contracts signed to date and assess their different aspects? If not, can the Commission explain why its political judgement goes against the overriding public interest of making the contracts public?
- 3. Will the Commission make available all past, current and future contracts signed with pharmaceutical companies – without redacted texts, in full transparency and openness towards the public?